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Purpose of Thesis 
The purpose of this thesis is to explore the issue of gene therapy. Background 
infonnation is given to explain what gene therapy is and some of the ways it is 
accomplished. A discussion of organizations which regulate gene therapy is given. Also, 
some of the ethical issues that arise due to gene therapy are introduced. A detennination 
of public knowledge is attempted by the use of a survey which was distributed to students 
and professionals. Statistical analyses are computed using the survey data to detennine 
whether any correlation exist between certain groups of subjects and their responses to 
some of the survey questions. Finally, the thesis contains a section devoted to suggestions 
for further study. 
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-Introduction 
One of the fastest growing fields of Biology is Genetics. Genetics is the study of 
heredity (5). However, the mechanism of inheritance took many years to work out. 
Individuals such as Mendel, Sutton, Morgan, Miescher, Watson, and Crick came across 
many discoveries which were instrumental in solving the puzzle of inheritance (14). Not 
only were the discoveries made by these people important in their own right, but they laid 
a basis that would assist in future genetic discoveries and techniques. 
The field of Genetics studies the passing on of traits from one generation to 
another; a concept known as heredity (5). People are susceptible to inheriting deleterious 
traits as well as beneficial or normal traits. In some cases these bad traits may not be 
extremely harmful to the individual, such as in Marfan's syndrome (14). However, some 
inherited mutations may be deadly, such as in the case of Tay-Sachs disease (14). Using 
techniques. such as genetic screening and gene mapping makes it possible to learn more 
about these unwanted genes and how to treat them (5). 
This paper will focus on gene therapy, ethical problems that arise due to gene 
therapy, and the public's knowledge of gene therapy. Gene therapy is used to correct 
sequences of DNA in somatic cells or in the germ cells of an individual (12). The goal of 
gene therapy is to introduce normal genes into cells where abnormal genes have caused a 
disease(s) (5). However, before gene therapy is discussed the biological and genetic basis 
of inheritance will be presented. 
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Background Information 
The human body is made up of approximately fifty trillion cells. These cells must 
contain information that allows them to function normally. Ifthere was no such 
mechanism, cells would not be able to divide and make new cells. Fortunately, cells do 
possess thlS essential information in the form of genes, which are portions of DNA 
molecules (14). When the cells divide, DNA has been replicated and identical copies are 
passed on to the two daughter cells of each parental cell (14). This process, know as 
mitosis, ensures that each new cell contains all of the genes that were present in its 
parental cdl (14). Each cell contains somewhere around one hundred thousand known 
genes (12). 
There are two types of cells in the human body which contain these genes. The 
first type a.re somatic cells. Somatic cells are found in the skin, intestine, blood-forming 
tissues, and most other tissues of the body (14). All of these cells divide by the process of 
mitosis (14). They are not involved in fertilization and have no influence over an 
individual's offspring. The second type of cells are the germ-line cells, or sex cells. These 
cells include egg cells in females and sperm cells in males (14). Germ cells divide by 
meiosis, a process which results in cells which have only one copy of each gene (14). 
Germ cells. are involved in sexual reproduction. Therefore, these sex cells can be 
considered the vehicles that transfer the parent's genes to the offspring. 
Prospective parents hope for a healthy and happy baby. Unfortunately, this is not 
always the case. Often a gene that is inherited from one, or both parents, may be a 
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mutated gene. The mutation may not lead to any serious problems or it may cause a 
severe genetic disease. A parent that expresses a deleterious trait that is heritable may 
pass that gene on to his or her offspring. However, there are techniques such as gene 
therapy that may prevent a harmful gene from being passed on to an offspring (12). 
Gene Therapy Techniques 
Gene therapy is a relatively new genetic technique used to eliminate or prevent the 
inheritance of deleterious genes (12). Gene therapy can be used to correct genes in 
somatic ceUs and germ cells (12). It is not just one simple procedure. There are 
numerous ways in which it can be done. Nontargeted delivery of genes can be 
accomplished by viruses or by chemical or physical means (13). 
Gene insertion is a procedure in which a new version of a gene is introduced into a 
cell (13). A common method of gene insertion employs the use of viruses. Viruses love 
to invade foreign cells and stick their own genes into the host's genetic material, thereby 
putting th(;~ virus in control (5). A virus is first crippled and rendered harmless (13). Then, 
the virus is altered so that it can carry genes into a target cell but not infect other cells 
(13). The term vector is often used to describe a virus treated in this way. The gene 
which is to be treated is removed from the patient's cell and altered with the correct 
sequence (13). Once this has been completed, the treated gene is inserted into the virus 
(13). The individual is then infected with the carrier virus so that the treated gene can be 
inserted into the cells ofthe individual (13). The newly inserted gene assumes the function 
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of the patient's own defective gene (5). Other kinds of viruses that travel to specific parts 
of the body are also being explored as vehicles to deliver desired genes (3). 
Chemical methods involve the mixing of many copies of DNA carrying the healthy 
gene with a charged substance (13). Some examples ofa charged substances are calcium 
phosphate, DEAE-dextran, and various lipids (13). Once this mixture is created it is 
dumped into recipient cells (13). The chemicals in the mixture disrupt the cell membrane 
and transport the DNA into the interior (13). This method is rather ineffective however. 
Only about 1 cell in 1,000 to 100,000 integrates the healthy gene (13). 
A physical method of gene insertion is microinjection. A fine glass pipette and 
electroporation (exposing cells to an electric shock) are involved (13). The electric shock 
renders the cells permeable to the DNA in the surrounding medium from the injection 
(13). The DNA can then be incorporated into the cells. This procedure is more efficient 
than the chemical method. Nearly 1 cell in 5 may take up the foreign gene (13). 
Types of Gene Therapy 
There are two types of gene therapy. One type focuses on the somatic cells of an 
individual (12). Somatic cell interventions can be viewed as standard, medical 
interventions that repair damaged structures (11). The second type is germ-line gene 
therapy (1:2). This type of therapy is directed at the egg or sperm (12). It may also be 
done during the very early stages of development after fertilization (12). More 
specifically, this type of therapy is only practical ifit is attempted within hours of 
fertilization (12). 
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Somatic cell gene therapy has many advantages over sex cell therapy. One such 
advantage is that the therapy can be performed during any stage of development of the 
individual (12). A second advantage relates to gene therapy experiments on somatic cells. 
Experiments on somatic cells may be done on samples or parts of organs, rather than the 
entire organ (12). This lowers the risks of failure because a failed experiment does not 
cause the) oss of an entire organ (12). Also, somatic cell experiments can be repeated 
numerous times on the same individual (12). A final advantage of somatic cell gene 
therapy is that it is beneficial directly to the person receiving the treatment and does not 
become a part of the gene pool (12). 
Unfortunately, there are some disadvantages to somatic cell gene therapy. One 
disadvanta.ge is that diseases affecting more than one type of tissue may not be treated by 
somatic cdl gene therapy (12). This is due to the fact that each cell or each tissue would 
have to be treated. Another disadvantage is that this type of therapy may not be effective 
on cells that do not divide (12). This would eliminate treatment of brain, nerve, and 
muscle cells. 
Germ cell gene therapy has a an advantage. In germ cell therapy, once a defect has 
been corrected, that same defect much less likely to be inherited by an offspring (12). If 
the gene was corrected and inherited, then that offspring will now have a copy of the good 
gene in its genome to pass on to its own offspring. Theoretically, a deleterious trait could 
be eliminated from a population this way. 
The disadvantages of sex cell gene therapy seem to greatly outnumber the 
advantages. Only a few will be mentioned in this paper. One disadvantage is that many 
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types of diseases are too complicated to treat (12). Some of these diseases may be 
inherited as autosomal dominant disorders, or they my be due to the interaction of multiple 
genes (12). Another disadvantage is that the responsible gene must have been located 
within the genome previously (12). If the location ofa gene causing a genetic den~ct has 
not been fc)und, then there is no way to treat it until it is located. Finally, germ-line gene 
therapy is a very controversial issue that has many ethical implications (11). The ethical 
aspects of a technique or procedure must be thoroughly examined before any action 
should take place. 
Regulating Gene Therapy 
Before research involving human subjects can be initiated, two types of 
committees are required to examine experiments and procedures. The Institutional 
Review Board (IRB) ensures that the research complies with the Department of Health 
Service's (DHHS) regulations (2). This is necessary for the protection of human subjects. 
The Institutional Biosafty Committee (IBC) must approve all research which involves 
gene insertion (2). 
Several federal agencies are involved in regulating gene therapy. The National 
Institute of Health (NIH) approves research grants to do gene therapy research and 
ensures that federal research guidelines are followed (12). NIH is currently the most 
active agency involved in regulating gene therapy (12). The Recombinant DNA Advisory 
Committe(~ (RAC) is a component of NIH. The RAC was established to develop 
guidelines for gene therapy research on human subjects (12). 
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- Another federal agency involved in regulating gene therapy is the Food and Drug 
Administration (FDA). The FDA becomes involved in regulating gene therapy if products 
such as nucleic acids or genetically modified viruses are to be used (12). 
The Ethics Advisory Board is made up of experts in the fields of ethics, law, 
medicine, and other experts on current topics (12). Its members are non-governmental 
individuals. This board is not a permanent agency, but is reconstituted when needed (12). 
The Ethics Advisory Board reviews questions and issues related to the progress of gene 
therapy (12). 
"In 1980, at the urging of the major religious groups in this country, the President 
requested that the President's Commission for the Study of Ethical Problems in Medicine 
and Behavioral Research examine the topic of human genetic engineering" (2). Many 
other fedeTally constructed committees are now exploring gene therapy. These 
committees include the following: The Human Gene Therapy Subcommittee, The 
Biotechnology Science Coordinating Committee, The Office of Technology Assessment, 
and The Biomedical Ethics Board (2). 
Ethical Concerns Involving Gene Therapy 
When considering gene therapy, many ethical issues arise. Whether or not gene 
therapy procedures ought to be done must be considered. A commentary entitled "Should 
scientists conduct experiments on the germ-line of humans?" shows two opposing views 
on that issue. David F. Koshland Jr. supports experimentation in the article but Stuart 
Newman is opposed to the experimentation (8). Often the ultimate consequences of new 
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research are not considered. This was exemplified in the film Jurassic Park. The 
scientists in the movie genetically engineered dinosaurs that escaped from their 
imprisonment and killed people. The rich entrepreneur was so overcome by what his 
scientists were capable of doing that he did not ask, should we be doing what we are 
doing? Fortunately, no one is genetically engineering dinosaurs in the real world, yet we 
do possess technologies that can be just as potentially dangerous. Before we decide 
whether to use a technology, we should consider the ethical implications it may have. 
Ethical questions do not have a correct answer. "The decision-making process is 
further complicated by the observation that very few problems present genuine choices of 
unquestionable good over unquestionable evil" (7). If they did, we would not still be 
debating the issue of abortion. Someone may disagree with both extremes of an issue, yet 
agree with some aspects of one argument or both arguments. A suggestion to make an 
ethical decision may be to open-mindedly weigh as many aspects of the issue as possible 
before deciding. 
This may be a hard task for one individual to complete. However, for a committee 
or group of individuals to make an ethical decision it may be an entirely different story. It 
seems that it would be extremely difficult to have all the members of a committee see 
eye-to-eye on ethical issues. Often, there may be members with totally opposed views that 
will never agree with one another. 
There are many unsolved ethical issues involving gene therapy. Genetic 
manipulati on of the germline could produce damage in future generations (1). This 
statement eould arouse ethical debate. Ifwe do not know the exact effect on future 
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generations should the procedure be done? Some people may feel that this is a risk worth 
taking while others may not. 
Another question would be, do infants have the right to inherit a manipulated 
genome? (1). An issue such as this deals with the rights of the individual. However, how 
do we determine what rights the individual is allowed or is not allowed? Also, who should 
make a decision such as this? Maybe it should be the responsibility of geneticists. An 
ethics committee could be established to make the decision. There are numerous 
alternatives, but are any of these groups the correct choice? 
There are also ethical dilemmas concerning informed consent. " ... does the concept 
of informed consent have any validity for patients who do not exist. .. " (1). In other 
words, an unborn child cannot express informed consent about gene therapy. Does this 
mean that the procedure should not be done? That is an ethical question that may undergo 
considerable debate. 
Another ethical question relates to the availability of treatment. If gene therapy 
can only be available to a few, and many are seeking it, how do we decide who receives it? 
The decision could be made by a doctor. It could also be left up to an ethics committee. 
"If the number of potential subjects exceeds the number of places available in the study, it 
may be very difficult to avoid making judgments about comparative social worth" (10). 
Factors such as the patient's age and the disease to be treated may limit the scope of this 
problem (10). 
A l1nal controversial issue is just how far should we go with gene therapy 
techniques and research? Ifwe can alter genes to treat a disease, then maybe we can alter 
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able to have made-to-order babies? " ... at what point do we cross the line into "playing 
God"?" (1). This is an important issue that could charge heated controversy. Do we have 
the right to manipulate our naturally inherited genes? If we do, how far do these rights 
extend? "The underlying concern among those who object most strenuously to the use of 
human gene therapy is that the new techniques eventually might be employed to alter 
genetic traits in normal individuals" (10). If gene therapy does reach this extent, can we 
consider it gene therapy any longer? 
Gene Therapy and Public Knowledge 
Unfortunately, many people are ignorant about gene therapy. This statement can 
be supp01ted by the data obtained from the surveys which were distributed. In all research 
done for this thesis, a number or percentage of how many people did or did not know 
what gene therapy is could not be found. Some people have heard of it yet could not 
correctly say what it is if asked. Therefore, how can we make sound ethical decisions for 
people with limited knowledge? When decisions are being made for the general public, 
ought they know what it is that is being decided? A governmental official may announce 
to the public that gene therapy will only be available to medically related cases. People 
who do not know what gene therapy is will have no use for this information, whether they 
have a treatable disease or not. 
To determine the public's knowledge about gene therapy a survey was created. 
The survey asked questions to determine how much people know or do not know about 
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can be found in the appendix of this paper. 
The survey was given to students, geneticists, and other medical professionals. 
The first question of the survey was used to determine what grade level the subjects were 
in at present. At this point in the paper only student responses will be discussed. The 
subjects were members of all undergraduate grade levels: freshmen, sophomores, juniors, 
and seniors. The second question of the survey was used to determine the majors of the 
subjects. The students surveyed fell into a wide variety of majors (Tables 1 & 2). 
Table 1. "Class Distribution" 
Clas.s Level 
1----
Percentages 
Freshmen 38.6% 
Sophomores 30.2% 
Juniors 14.9% 
S{:niors 16.3% 
Table 2 shows the distribution of the subjects majors. 
Table 2. "Major Distribution" 
1---. 
Majors Percentages 
Social Science 1l.4% 
Science 12.9% 
Communication 1l.4% 
Education 1l.9% 
Business 2l.3% 
Fine Arts 5.4% 
Math and Computer Science 5.0% 
Architecture 4.5% 
Undecided 10.4% 
Miscellaneous 5.9% 
11 
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A sample such as this should produce people with none to much knowledge 
about the topic of gene therapy. 
The next aspect of the survey dealt with the subjects' background knowledge in 
Biology and gene therapy. The question asked whether the students had taken specific 
biology classes or ethics classes. The classes placed in the survey were an introductory 
biology class (Bio 100), Genetics (Bio 2140, Cell Biology (Bio 215), Honors Biology (Bio 
299), BioEthics (Bio 492), any ethics classes, or none. Table 3 summarizes the subjects' 
responses. 
Table 3. "Background Information of Students" 
Classes Taken Number of Students 
~-
Bio. 100 84 
Bin. 214 3 
Bin. 215 3 
Bin. 299 52 
Bio.492 1 
Ethics 13 
None 60 
The majority of the two hundred and two subjects have had at least one of the 
classes in question. However, 29.85% of students no background in Biology or Ethics. 
Subjects with no background in these classes have probably never had formal college 
course work involving the topic of gene therapy. However, the subjects may have been 
exposed to the topic through television or personal reading. 
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The next question on the survey asks the subjects to indicate what gene therapy is. 
The data collected are displayed in Table 4. 
Table 4. Responses to "What is Gene Therapy?" 
Possiblt~ Responses Number of Replies 
The r,emoval of 19 
unwanted DNA. .. 
The cutting of DNA 13 
with endonucleases 
Manipulating a person's 180 
gene in the attempt... 
Inserting the DNA of 5 
one speCIes ... 
There was a total of 217 responses to this question. However, the sample 
consisted of only 202 subjects. This indicates that some people replied with more than 
one answer. Response 3 gives the answer that shows the general purpose of gene therapy. 
The data indicate that even though the subjects may not have a strong background in fields 
relating to gene therapy, about three fourths or more of them understand the goal of gene 
therapy. 
Table 5. "Which Diseases can be Treated by Gene Therapy?" 
Diseases Number of Responses 
1---. 
Huntington's Disease 78 
Polycistic Kidney Disease 15 
Familial Hypercholesterolemia 27 
Phenylketonuria 48 
Beta·.zero-thalassemia 13 
Adenosine Deaminase 29 
Malignant Melanoma 18 
AIDS 6 
-
Lesh Nyhan Syndrome 18 
None 54 
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-Table 5 is a display of the responses to which diseases can be treated by gene 
therapy. 
Table 6. "Do You Know the Difference Between Somatic Cell and Sex Cell Gene Therapy?" 
E Responses Number of Replies Yes 32 No 170 ._--'------
Since gene therapy can be done on both sex cells and somatic cells this question of 
the survey indicates that most subjects do not have an in-depth understanding of gene 
therapy. If the respondents do not know the difference between the types of therapy then 
they cannot know how gene therapy can effect each type of sex. Somatic cell therapy 
--
would affe:ct only the individual receiving the therapy and sex cell therapy would affect the 
individual's offspring. 
The next question dealt with ethical problems concerning gene therapy. The 
replies are summarized in the Table 7. 
Table 7. "Ethical Problems with Gene Therapy" 
f----
Replies Number of Responses 
Some religious beliefs ... 132 
Gene therapy is too time 26 
consuming 
Gene the rapy costs too 70 
much 
There are no laws 75 
involving .. _ 
There may be philosophical 95 
beliefs ... 
-
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Over half of the subjects felt that religious beliefs may impede gene therapy. Also, 
approximately half of the respondents felt that philosophical beliefs may affect attitudes 
about gene therapy. Response 4 is incorrect. There are laws and regulations involving 
gene therapy. Many organizations exist that place strict rules upon gene therapy. 
However, 75 people did not know that they existed. 
The next question asked the subjects whether they would have gene therapy done 
on themselves. Out of 202 responses, over 60% indicated they would have gene therapy 
done on themselves (Table 8). 
Table 8. "Would You Have Gene Therapy Done on Yourself?" ERe.pon.e. 
Yes 
No 
Number of Replies 
128 
74 
Subjects were then asked how gene therapy should be funded. The responses to 
this question were also somewhat interesting. The responses are displayed in Table 9. 
Table 9. "How Should Gene Therapy Be Funded?" 
Responses Number of Replies 
Health insurance 119 
Governmental funding 41 
through taxes 
The person seeking the 67 
therapy should fund it. .. 
It should not be funded 11 
because ... 
Although most subjects indicated that gene therapy should be funded by health 
insurance, 41 subjects thought gene therapy should be funded through taxes. In a society 
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of funding. Only 5.45% of the subjects were against gene therapy being done at all. 
The final question dealt with regulating gene therapy. The subjects were asked 
what kinds of restrictions or regulations should we place on gene therapy. Their replies 
are found on Table 10. 
Table 10. "What Kinds of Restrictions or Regulations Should We Place on Gene Therapy?" 
Responses Number of Replies 
Gene therapy should only be available 13 
to people who can afford it 
Gene therapy should only be allowed 153 
in medically related cases 
Gene th{:rapy should be available to 31 
anyone for any reason 
Gene therapy should not be 12 
performed at all 
The majority of subjects believed that gene therapy should be available only in 
medically related cases. This suggests that most people are concerned with treating 
disease to help people rather than producing children with specific characteristics. One 
more person has now responded that gene therapy should not be done at all. Twelve 
people responded with that answer, yet in the last question only eleven people replied with 
that answer. 
In order to determine whether grade level had an influence on student knowledge 
-
of gene therapy, the question of whether the students knew the difference between 
somatic cell and sex cell gene therapy was examined. The null hypothesis was that there 
-
was no significant difference between the number of "yes" responses as the grade level 
16 
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increased. The alternate hypothesis was that there is a significant difference in the number 
of "yes" re!sponses as grade level increases. For all of the statistical tests, the response of 
"yes" was given a value of 1 and the response of "no" a value ofO. 
The test chosen was a two sampled t-test with a pooled variance. The two sample 
test was appropriate because a comparison was being made between two populations 
rather than one population being compared to a known mean. In the second case a one 
sample test would have been the best to use. 
with 
The following equations were used to obtain the statistics: 
x = 
n 
n Lx; 
;=1 
n 
L (x;_i)2 
S2 = .:....;=.:....1 __ 
x n-l 
s = p 
x-y 
t= 
spJk+k 
(n-l )s;+(m-l )s~ 
n+m-2 
where n is the number of elements of the x data range and m is the number of elements of 
the y data range (6). X bar, in the first equation, represents the sample mean (6). The 
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to calculate the t statistic (6). The final equation is used to compute the pooled variance 
which is used in the calculation of the t statistic (6). 
Before the t-tests could be computed, the means and variances for all of the class 
levels wer,e determined using the first two equations. It is also important to take into 
account the size of each sample which is being tested. For all of the t-tests the null 
hypothesis, is not rejected if the tabled value falls below the .90 significance level. The 
results ofthese computations are summarized in the following table of values. 
Table 11. "'Individual class statistics" 
Grad,e Level n X S2 x 
'-----
Freshman 79 0.063291 0.0600454 
Sophomore 58 0.189655 0.156382 
Junior 30 0.233333 0.1850575 
Senior 34 0.235294 0.1853832 
These results were used to compute the pooled variances and the t statistics. The 
pooled variance values, the t statistics, the significance levels at which the results would 
allow the null to be rejected, and whether the null is rejected or not are shown in Table 12. 
-
18 
,- Table 12. "Summary oft-test results" 
Compruison sp t Significance Reject Null or 
Level Fail to Reject 
Null Hypothesis 
--
Fresh'!Soph. 0.113945 -6.560348 0.995 Reject 
Soph.!J uniors 0.1666041 -1.1657632 0.75 Fail to reject 
Juniors/Seniors 0.1852309 -0.0422644 0.6 Fail to reject 
Fresh.!Juniors 0.1091328 -7.2654385 0.995 Reject 
Fresh.!Seniors 0.1129192 -7.426428 0.995 Reject 
Soph.!Stmiors 0.1675995 -1.2607325 0.75 Fail to reject 
When analyzing the t-test results for this question it was found that the number of 
responses .of "yes" for all ofthe grade levels was significantly greater than the number of 
"yes" responses made by the freshmen. These results indicate that most freshmen have 
probably not a class dealing with the types of gene therapy yet. 
However, when examining the other test results there was not strong enough 
evidence to support the hypothesis that as grade level increases, so does knowledge of 
gene therapy, The comparisons of sophomores and juniors, juniors and seniors, and 
sophomores and seniors, having significance levels of<.75, <.90, and <.75 respectively, 
cause the null not to be rejected. Therefore, grade level does not seem to be correlated 
with the amount of knowledge the subjects have about the types of gene therapy. 
A second set oft-tests involved the question of whether or not the subjects would 
have gene therapy done on themselves if they had a genetic disease. The null hypothesis 
was that there was no significant difference in the number of "yes" responses as grade 
level increased. The alternate hypothesis was, as grade level increased the number of 
-
"yes" responses would increase. Tables 13 & 14 summarize the results. 
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Table 13. "Individual class statistics" 
Grade Level n x s; 
f---. 
Freshman 79 0.56962 0.248296 
Sophomore 58 0.687655 0.2177858 
Junior 30 0.533333 0.2574713 
S(;:nior 34 0.676471 0.22549 
Table 14. "Summary oft-tests" 
Compatisons sp t Significance Reject or Fail to 
Level Reject Null 
f----. 
Fresh./Soph. 0.2358957 -2.9427619 >.995 Reject 
Soph./Juniors 0.2319282 2.9970903 <.60 Fail to Reject 
Juniors/Seniors 0.2409779 -2.3713072 >.99 Reject 
Fresh./Juniors 0.2508159 0.6746164 <.60 Fail to Reject 
Fresh./S eniors 0.2417407 -2.1549768 >.975 Reject 
Soph./S.~niors 0.2206419 0.2766424 <.60 Fail to Reject 
For these analyses there were only three situations in which the null hypothesis can 
be rejected. Those three cases are in comparisons of freshmen and sophomores, juniors 
and seniors, and freshmen and seniors. In this study sophomores were most willing to 
have gene therapy done if they had a genetic disease. These tests do not appear to show 
any correlation between grade level and likelihood to have gene therapy done. 
The comparisons of the sophomores and juniors, freshmen and juniors, and 
sophomores and seniors, significant at levels all <.60, are not strong enough to conclude 
that the higher of the two grade levels has a significantly greater response of "yes". The 
junior class appeared to be the odd group in the study. Table 14 shows that the group of 
-
juniors w(~re less willing to have gene therapy then the other classes. To sum things up, 
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there is no strong evidence to support the hypothesis that the higher grade level the more 
likely one is to have gene therapy if that person had a genetic disease. 
Ne:xt, replies of science majors were compared with those of non-science majors 
concerning the same two questions. The first test dealt with whether the subjects knew 
the difference between somatic cell and sex cell gene therapy. The null hypothesis was the 
number of "yes" responses of science majors are not significantly greater than that of 
non-science majors. The alternate hypothesis was the number of "yes" responses of 
science meyors is significantly greater than non-science majors. The statistical results are 
found in the following tables. 
Table 15. "Individual major statistics" 
E! Sci Non-ajor n X S2 x ence 26 0.3076923 0.2215385 SCIence 175 0.1314286 0.1148112 
Table 16. "Summary oft-tests" 
Comparison S2 p t Significance Reject or Fail to 
Level Reject Null 
Sci.lNon-sci. 0.1330089 -6.3050691 >.995 Reject 
These results strongly support that there is a correlation between major and 
knowledg{~ of gene therapy types. Science majors have a much greater understanding of 
the types of gene therapy than non-science majors according to Table 16. 
Thl~ final test was used to determine whether science majors were more likely to 
have gene therapy if they had a genetic disease than non-science majors. The null 
-
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less than that of non-science majors. The alternate hypothesis was that the number of 
"yes" responses of science majors was greater than that of non-science majors. The data 
of these calculations is displayed in the next two tables. 
Table 17. "Individual major statistics" 
E; Sc: Non-aJor n X s2 x lence 26 0.6923077 0.2215385 SCIence 175 0.614286 0.2389491 
Table 18. "Summary oft-tests" 
Comparison sp t Significance Reject or Fail to 
Level Reject Null 
_. 
Sci.INon-sci. 0.2368321 -1.5674096 >.90 Reject 
-
The >.90 significance level found for this test provided strong evidence that there 
is a correlation between major and willingness to have gene therapy for a genetic disease. 
It was determined that the science majors were more likely to agree to have gene therapy. 
The same survey was distributed to a group of professionals. These professionals 
included geneticists and professors of Genetics. The results of those surveys are 
summarized in the following tables. The replies of the geneticists should be representative 
of an educated population on the topic of gene therapy. It is interesting to see the 
differences, in the replies between the population of professionals and the population of 
students. 
-
22 
-Table 19. "What is gene therapy?" Professionals'replies. 
Responses Number of Replies 
-. 
The removal of unwanted 1 
DNA .. 
The cutting of DNA with 1 
endonucleases 
Manipulating a person's 9 
genes in the attempt... 
Inserting the DNA of one 1 
species ... 
All of the responses in Table 9 are aspects of gene therapy. However, response 
three is the correct answer. All of the professionals answered with response three. One 
professional replied with all of the choices which is also correct. These data corresponds 
well with the student responses. The majority of student responses were choice three as 
well. 
The second question was "Which disease can be treated by gene therapy?". The 
professionals' responses are displayed in the following table. 
Table 20. "Which disease can be treated by gene therapy?" 
f----. 
Type of Disease Number of Responses 
Humigton's Disease 0 
Polycistic Kidney Disease 0 
Familial Hypercholesterolemia 1 
Phenylketonuria 0 
Beta-zero-thalassemia 0 
Adenosine Deaminase 7 
Malignant Melanoma I 
AIDS 1 
-
Lesh Nyhan Syndrome 0 
None 1 
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The responses to this question were very different than those of the students. The 
most common response among the students was Huntington's disease. That particular 
disease is not treatable by gene therapy at the present time. The professionals' responses 
involved only five choices: Familial Hypercholesterolemia, Adenosine Deaminase, 
Malignant Melanoma, AIDS, and none. In all of my research I found only choice, 
AdenosinE: Deaminase, to be treatable. However, experimental gene therapy procedures 
are being tried on nearly all of the other diseases according to many of the professionals' 
comments on the survey. A much higher percentage of professionals chose ADA than the 
students did. This indicates that the professionals are acquainted with current gene 
therapy treatments. However, the students appear to be lacking of that knowledge. 
The next question also involved the subjects knowledge of gene therapy. The 
question was asked to determine if the professionals knew the difference between somatic 
cell gene therapy and sex cell gene therapy. Table 21 contains those results. 
Table 21. "Do you know the difference between somatic cell and sex cell gene therapy?" 
Yes 
No 
Number of Replies 
7 
2 E Responses _~-------J 
The table shows that the majority of subjects knew the difference. Only 77.8% of 
the professionals knew what the difference was (Figure 13). The professionals proved to 
be much more knowledgeable than the students. Only 15.8% of the students knew the 
difference (Figure 6). This low percentage may be due to the students lack of experience 
in the fields of biology and genetics. 
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The next question deals with ethical problems that may arise due to gene therapy. 
The responses are summarized in the following table. 
Table 22. "What are some ethical problems with gene therapy? 
1---. 
Responses Number of Replies 
Some religious beliefs ... 5 
Gene therapy is too time 1 
consummg 
Gene therapy costs too much 4 
There are no laws involving 3 
gene therapy 
There may be philosophical 3 
beliefs against gene therapy 
None 3 
The response of "None" was also included since many professionals commented 
that on th(: surveys. Again, these results were similar to those of the students. The most 
frequent answer was response number one. Most subjects in both populations were 
concerned with the religious views about gene therapy. However, many of the 
professionals believed that the cost of gene therapy was the second most important 
concern. The students felt that philosophical views about gene therapy were the second 
most important aspect. 
The survey then asked if the subjects would have gene therapy done to themselves 
if they a g(~netic disease. The responses are displayed in Table 15. 
Table 23. "Would you have gene therapy done on yourself if you had a genetic disease?" 
-
E Responses Number of Replies 1{es 9 ______ N_o ____________ ~ ____________ O ____________ ~ 
25 
Every one of the professionals agreed that they would have gene therapy if they 
had a gem:tic disease. In comparison to the student responses the professionals 
outnumbered them greatly in their response of "yes". Only 63.4% of the students replied 
that they would have gene therapy done (Table 8). This response is most likely do to lack 
of knowledge about gene therapy on the part of the students. 
The next question dealt with the funding of gene therapy. The following table 
contains that data. 
Table 24. "How do you think gene therapy should be funded?" 
Responses Number of Replies 
--
Health insurance 9 
Governmental funding 4 
-
through taxes 
The person seeking the 1 
therapy should fund it. .. 
It should not be funded 0 
because ... 
The professionals' responses were similar to those of the students. Both 
populations believed that health insurance was the best method of funding gene therapy 
(Tables 9,24). There was a difference in the second most frequent choice. The 
professionals felt that funding through taxes was the next best way offunding. However, 
the students chose personal funding as their second choice. These data indicate that the 
subjects would rather be covered by health insurance than directly paying for gene therapy 
in the foml of taxes or with personal funds. 
-
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The final question dealt with restrictions. The question was used to determine in 
which cases gene therapy should be available. Table 25 displays the professionals' 
responses. 
Table 25. ''What kinds of restrictions or regulations should we place on gene therapy?" 
Responses Number of Replies 
Gene therapy should be available only 0 
to people who can afford it 
Gene therapy should only be allowed in 9 
medically related cases 
Gene therapy should be available to 0 
anyone for any reason 
Gene therapy should not be performed 0 
at all 
The professionals chose response two by 100% (Figure 17). The students also 
-
chose response two as their most frequent choice (Table 10). However, the students also 
chose the other responses. The professionals appeared to place a priority on health. The 
students also seemed to feel that the priority of gene therapy should be to treat diseases. 
Conclusion 
The purpose of this thesis was to determine public knowledge of gene therapy and 
opinions on ethical issues involving gene therapy. Background information on gene 
therapy was presented first to give an understanding of the uses of gene therapy. The 
advantages and disadvantages of the types of gene therapy, and some of the ethical issues 
that arise due to gene therapy were then discussed. 
-
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A survey was given to students and professionals to determine the knowledge the 
subjects had about gene therapy and what they feel are some of the ethical arguments that 
may arise from gene therapy. 
One prediction was that the student population was not fully knowledgeable of 
what disea.ses could be treated by gene therapy. The students chose Huntington's disease 
more than any of the others as the disease that could be treated. Huntington's disease is an 
autosomal dominant disease that is a very unlikely candidate for treatment at this time. 
The professionals chose Adenosine deaminase more often than any other disease. This 
disease is the only one that has been documented to be treatable at the present time. Most 
of the oth(~rs an being tested experimentally at this time. 
Secondly, the student population was not acquainted with the types of gene 
therapy. Only 15.8% of the students knew the difference between somatic cell and sex 
cell gene therapy (Figure 6). However, with a sample size of9, 77.8% of professionals 
knew the difference (Figure 13). 
As for ethical concerns, occupation, grade level, or major do not appear to have a 
great effect on a person's beliefs. Tables 7, 10,22, and 25 help to support this claim. On 
Tables 7 and 22, response 1 had the most replies. On Tables 10 and 25, choice 2 was 
answered most frequently. The student population and the professional population chose 
the same r.eplies most frequently. Also, the student population was very diverse. 
Therefore, students from all majors and grade levels were all contributing to the most 
frequent responses. 
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One ethical question involved how gene therapy should be regulated. When the 
data for this question are examined, the majority of students and professionals believed 
that gene therapy should be allowed only in medically related cases (Tables 10, 25). Many 
people sec::m to be against the "abuse" of science. Gene therapy has the potential of being 
abused. Some of the strongest supporters of genetic research are the first to admit the 
potential for its abuse (15). By examining Tables 10 and 25, it appears that people may 
realize that gene therapy has the potential of being abused and that is why the majority of 
them feel it should be restricted to only medical uses. 
It is very difficult to determine what an ethical decision should be based on. In the 
research done for this thesis no agreement could be found on a correct method to go 
about decision-making. However, some individuals seemed to mention that an individual's 
values were important. "Differences in ethics means that underlying value structures 
differ. .. " (4). This statement is an example that values affect a person's ethics. A second 
factor in ethical decision-making that was mentioned was that of education. "Certainly if 
society is to deal with the moral-ethical issues raised by the application of advances in 
medical gmetics, a reasonable measure of genetic literacy is essential" (9). Therefore, it 
appears that a person should be genetically literate, or educated, to make an ethical 
decision about gene therapy. This statement can also be supported by the statistical tests 
done on science major versus non-science majors. 
The statistical analyses which were performed showed some interesting results. It 
was hypofhesized that grade level would have an effect on the subjects knowledge of gene 
therapy type. However, when the results were examined, this not found to be the case 
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(Table 12). There must be other factors influencing the subjects knowledge. Some of 
these factors may be high school education, personal curiosity, or possibly discussion of 
the topic with a family member or other acquaintance. Any of these factors may have 
allowed a subject to know the difference although he or she did not learn it in a college 
class. 
It was also hypothesized that grade level would influence willingness to have gene 
therapy. Again, the results did not support that hypothesis (Table 14). Many people 
replied that their religious beliefs would not allow them to condone gene therapy. The 
majority of subjects that said they would not have gene therapy, stated that their reason 
was lack of information on the subject. 
Next, it was hypothesized that science majors would be more likely to know the 
difference between the types of gene therapy. In this case the hypothesis appeared to be 
supported sufficiently (Table 16). The results observed may have been due to the subjects' 
education. Science majors are exposed to issues such as gene therapy in their science 
classes. Therefore, it seemed logical that they would know more about the topic. The 
data in Table 16 supports this statement. 
The final statistical analysis was to determine whether science majors were more 
willing to have gene therapy done to themselves than non-science majors. The hypothesis 
was that science majors would be more willing to have gene therapy than non-science 
majors. In this case the data observed supported the hypothesis (Table 18). Again, this 
may be due to the education of the subjects. A person that is better acquainted will what 
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gene therapy entails would probably feel more comfortable with undergoing the 
procedures. These statements can be supported by the data in Table 18. 
Science majors were determined to be more knowledgeable and more willing to 
have gene therapy (Tables 16, 18). Sciences majors have also had more background in the 
field of biology. It appears that education is important in understanding a topic such as 
gene therapy. This is supported in Table 16. The subjects are knowledgeable about the 
issue and therefore have a basis of information to use to base ethical decisions upon. 
However, what can less knowledgeable people base an ethical decision on? 
Everyday this society is bombarded with commercials on television for work-out 
equipment, health clubs, vitamins, and various other health care products. People read 
magazines which discuss topics such as exercise, eating right, and other aspects of 
personal health. Therefore, it appears that this society is concerned with being healthy. If 
a person has a treatable genetic disease then they have the opportunity to become more 
healthy be,~ause of treatments such as gene therapy. However, this thesis has shown that 
the general public (based on student responses) has very limited knowledge of gene 
therapy. \Vhat good is a treatment that no one knows about? This thesis may have shed a 
little light on the lack of knowledge about a useful therapy that could save lives. People 
need to be informed about gene therapy. However, there must be people, such as 
physicians, who must educate their patients about gene therapy. " .. .it is the moral 
obligation of the medical profession to make available any technology that can cure or 
prevent pathology leading to death and disability, in both the present and future 
generations" (15). Until this is accomplished we cannot truly deal with the ethical issues 
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.- that arise from it, and we cannot show the public that there may be hope for those people 
who could benefit from such a therapy. 
Suggestions for Further Research 
One idea for further research on this topic is to determine the knowledge and 
opinions of medical professionals on the topic of gene therapy. As was stated in this 
thesis, it is, important that the public be aware of beneficial treatments such as gene 
therapy. To obtain information about such procedures, people depend on their doctors to 
acquaint them with various therapies. However, if physicians are not up to date on 
current procedures then they cannot tell their patients about those treatments. It may be 
interesting to determine how much knowledge physicians truly have about the subject of 
gene therapy. Another suggestion is to discover whether medical students are educated 
about gene therapy so that they can advise their future patients. 
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I Figure 1. "Class Distribution" I 
61 (30.2%) 
30 (14.9'16) 
I_ Freshmen E3 Sophomores - Juniors D Seniors 
I Figure 2. "Major Distribution" I 
12 (5.9%) 
_Undecided 
III Science 
_ Fine Arts 
21 (10.4~) 
_ Communication D Education 
D Math, Compo Sci.D Architecture 
_ Business 
_ Miscellaneous [
_Social Science 
----,--------------------------------------------------------~ 
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1 Figure 3. "Background of Students" I 
Bio 100 Bio 214 Bio 215 Bio 299 Bio 492 Ethics None 
Biology Classes 
I Figure 4. "What is Gene Therapy?" I 
Response 1 Response 2 Response 3 Response 4 
Student Responses 
35 
-~igure 5. "Which Diseases Can be Treated by Gene Therapy?" I 
(4.9'11.) 
(15.7'11.) 
_ Huntington's 
iii PoIyciatic Kidney 
_ Familial Hypercholesterolemia 
o Phenylketonuria 
IIIlI Beta-zero-thalassemia 
_ Adenosine Deaminase 
_ Malignant Melanoma 
o AIDS 
o Lesh Nyhan Syndrome 
_None 
~gure 6. "Student Knowledge of Gene Therapy Types" 
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-c=!iQure 7. "Ethical Problems With Gene Therapy" 
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Qigure 8. "Would You Have Gene Therapy Done?" 
I_Yes _No 
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C Figure 9. "How Should Gene Therapy be Funded?" 
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Response 1 
Figure 11. "What is gene therapy?" 
~~a~'R~ 
Response 2 Response 3 
Responses 
Response 4 
Figure 12. "Which diseases can be treated by gene therapy?" 
Professionals' Responses 
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(8.3'11.) 
_ Huntington's Disease 
m Polycystic Kidney Disease 
Ell Familial Hypercholesterolemia 
D Phenylketonuria 
_ Beta-zero-thalassemia 
(0.0%) _ Adenosine Deaminase 
_ Malignant Melanoma 
_AIDS 
C Lesh Nyhan Syndrome 
o None 
-[ Figure 13. "Knowledge of Gene Therapy Types" ____________________ ~Pro~~~~~~~~·R~~~ __________________ ~ 
(77.8%) 
-
rigUre 14. "What are some ethical problems with gene therapy?" 
Professiona~' Responses 
6 
2 
o 
Response 1 Response 2 Response 3 Response 4 Response 5 Response 6 
-
Possible Responses 
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-/Figure 15. "Would you have gene therapy done if you had a genetic disease?" L Professionals' Responses. 
(100.0%) (0.0%) 
lFigure 16. "How do you think gene therapy should be funded?" L_ ProfessIonals' Responses. 
10 
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Response 1 Response 2 Response 3 Reaponse4 
PossIIIe RespoIMft 
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[ Figure 17. ''What kinds of restrictions should we place on gene therapy?" 
Professionals' R86pOI1S8$ 
(100.0'!II) 
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• Response 1 
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• Response 3 
o Response 4 
--
1. Axe you a: 
D Freshman 
D Sophomore 
D Junior 
D Senior 
D Graduate or Doctoral Student 
o Professor 
D Other Profession 
Cene Therapy Survey 
2. If you are a student please indicate your major, if you are a professor please indicate your 
department, or please indicate your profession. 
Only students need to answer question 1#3. . 
3. Have you ever taken any of the following classes? 
o Biology 100 
o Biology 214 
o Biology 215 
o Biology 299 
o Biology 492 
o Any ethics classes 
o None 
4. What is gene therapy? 
o The removal of unwanted DNA sequences from a person's chromosomes. 
D The cutting of DNA with endonucleases. 
o Manipulating a person's genes in the attempt to treat a genetic disease. 
D Inserting the DNA of one species into the genome of a different species. 
s. Which disease can be treated by gene therapy? 
D Huntington's disease 
o Polycystic kidney disease 
D Familial Hj"crcholesterolemia 
D Phenylketonuria (PKU) 
D Beta-zero-tbalassemia 
D Adenosine deaminase (ADA) 
D Malignant melanoma 
D AIDS 
o Lesh Nyhan syndrome 
o None 
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6. Do you know the difference between somatic cell and sex cell gene therapy? 
o Yes 
o No 
If yes, please explain. 
7. What are some ethical problems with gene therapy? 
o Some religious beliefs may conflict with gene therapy. 
o Gene therapy is too time consuming. 
o Gene therapy costs too much. 
o There are no laws involving gene therapy procedures. 
o There may be philosophical beliefs against gene therapy. 
8. Would you have gene therapy done on yourself if you had a genetic disease? 
o Yes 
o No 
Explain: 
-
9. How do you think gene therapy should be funded? 
o Health insurance 
o Governmental funding through taxes 
o The person seeking the therapy should fund it personally 
o It should not be funded because it should not be done 
10. What kinds of restrictions or regulations should we place on gene therapy? 
o Gene therapy should be available only to people who can afford it. 
o Gene therapy should only be allowed in medically related cases. 
o Gene therapy should be available to anyone for any reason. 
o Gene therapy should not be performed at all. 
Thank you for participating in this survey . 
..-
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